Pipeline

Robust CAR T CELLS Clinical Pipeline with Near-term Milestones

The adoptive transfer of CAR T cells has demonstrated remarkable success in treating blood-borne tumors. The use of CD19 CARs in leukemia (LAL) and lymphoma (DLBCL) received Breakthrough Therapy Designation by the FDA.

Aurora is pioneering the technology for solid tumors. We are using the next generation of CAR-T comprising of bi-specific CAR-T cells to target established solid Tumor Associated Antigens (“TAA’s”)

Aurora’s CAR clinical programs include multiple product candidates in clinical development against a variety of cancer targets in adults and children.

Product Agent Indication Pre-clinical Phase I/IIa Phase I(b)//II(a) Phase II(b)/III FDA Approval
AU105 CART GBM
(Newly Diagnosed)
         
AU101 CART
Intracranial
GBM
(Recurrent)
         
AU101 CART Sarcoma/ Osteosarcoma          
AU101 CART Breast          
AU105 CART Gastric          
AU55 CART Liquid          
AU180 CAR Allogenic          

Completed

Planned

Recurrent Glioblastoma

Aurora has planned for 2016 a Phase I/II trial in Recurrent Glioblastoma with intracranial delive...

Newly Diagnosed Glioblastoma

Aurora has planned for 2016 a Phase IIb/III trial in Newly Diagnosed Glioblastoma with intravenou...

Sarcoma

A Phase IIa Osteosarcoma trial with up to 36 patients receiving lymphodepletion followed by CAR T...

Metastatic Breast and Gastric Cancer

Herceptin is a HER-2 monoclonal antibody drug, currently FDA approved only for highly expressed H...